These two molecular groups of meningiomas exhibit differential clinical features: the non-NF2 meningiomas were nearly always benign, with chromosomal stability, and a cerebral localization at the level of the medial skull base; meningiomas with mutant NFE2 and/or chromosome 22 loss are often atypical and exhibit genomic instability and are usually localized at the level of the cerebral and cerebellar hemispheres [204]. This evidence concerns the gene NF2 and meningioma.